Approved & therapeutic
Dalbavancin
Dalvance
Dalbavancin is a semisynthetic lipoglycopeptide antibiotic for acute bacterial skin and skin structure infections, notable for a half-life long enough that a single dose treats a full course.
Also known as: Xydalba
- Status
- Dalbavancin is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- Approximately 14 days terminal half-life.
- How it's taken
- Single intravenous infusion, or two doses one week apart
- Mechanism
- Immune modulation
How Dalbavancin works
Dalbavancin binds the D-alanyl-D-alanine peptidoglycan terminus like vancomycin, but its lipophilic side chain anchors it in the bacterial membrane, increasing potency and dramatically extending its half-life through plasma protein binding and slow tissue release.
What research has looked at
- A single intravenous dose treats acute bacterial skin infection, eliminating the need for a peripheral line, daily infusions or an outpatient antibiotic service.
- This changes the economics of treating skin infection in patients who would otherwise be admitted purely for intravenous access, including people who inject drugs.
- Active against MRSA and streptococci, with greater in vitro potency than vancomycin.
- No therapeutic drug monitoring is required.
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- The extremely long half-life is a double-edged property: if an adverse reaction occurs, the drug cannot be withdrawn, and exposure continues for weeks.
- Prolonged sub-therapeutic tail exposure raises theoretical concern about selecting resistance.
- Infusion reactions similar to vancomycin if infused too rapidly.
- Elevated liver enzymes have been reported.
- Nausea, headache and diarrhea.
Sources
- FDA approved-drug listing for dalbavancin · U.S. Food & Drug Administration
- DailyMed prescribing information for dalbavancin · NIH · DailyMed
- PubMed research on dalbavancin single dose skin infection · NIH · National Library of Medicine
- DrugBank record for dalbavancin · DrugBank
Track Dalbavancin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Dalbavancin FAQ
What is Dalbavancin?
Dalbavancin is a semisynthetic lipoglycopeptide antibiotic for acute bacterial skin and skin structure infections, notable for a half-life long enough that a single dose treats a full course.
How does Dalbavancin work?
Dalbavancin binds the D-alanyl-D-alanine peptidoglycan terminus like vancomycin, but its lipophilic side chain anchors it in the bacterial membrane, increasing potency and dramatically extending its half-life through plasma protein binding and slow tissue release.
Is Dalbavancin FDA approved?
Yes. Dalbavancin is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Dalbavancin?
Reported half-life: Approximately 14 days terminal half-life.
How is Dalbavancin taken?
Single intravenous infusion, or two doses one week apart.
What side effects have been reported with Dalbavancin?
Reported in the sources: The extremely long half-life is a double-edged property: if an adverse reaction occurs, the drug cannot be withdrawn, and exposure continues for weeks; Prolonged sub-therapeutic tail exposure raises theoretical concern about selecting resistance; Infusion reactions similar to vancomycin if infused too rapidly; Elevated liver enzymes have been reported; Nausea, headache and diarrhea.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.